ORASONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORASONE (ORASONE).
Orasone (prednisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory cytokines, immune response, and adrenal function.
| Metabolism | Primarily hepatic via CYP3A4; also undergoes 11-beta-hydroxysteroid dehydrogenase interconversion with prednisolone. |
| Excretion | Primarily renal: ~80% as 17-keto metabolites and unchanged drug; biliary/fecal excretion accounts for <10%. |
| Half-life | Terminal half-life of 3-4 hours for prednisolone (active metabolite of ORASONE); clinically, duration of HPA-axis suppression is more relevant (12-36 hours) with longer effects at higher doses. |
| Protein binding | Prednisolone: 70-90% bound to transcorrin (corticosteroid-binding globulin) and albumin; binding decreases with higher doses (saturable). |
| Volume of Distribution | Vd: 0.4-0.6 L/kg for prednisolone; indicates distribution into total body water and peripheral tissues. |
| Bioavailability | Oral: 70-90% (fasting); IM: 100% (systemic); bioavailability is dose-dependent due to saturable protein binding. |
| Onset of Action | Oral: 1-2 hours; IM: 1-2 hours; IV: immediate (within 5 min) [anti-inflammatory effect]. Clinical effect may be delayed. |
| Duration of Action | Duration of anti-inflammatory effect: 12-36 hours after single dose; HPA-axis suppression may persist for 24-48 hours after short-term use. |
| Molecular Weight | 360.44 |
Adults: 5-60 mg orally once daily or divided twice daily; typical starting dose 5-40 mg/day. Route: oral. Frequency: once daily or every 12 hours.
| Dosage form | TABLET |
| Renal impairment | No dosage adjustment required for GFR ≥30 mL/min; for GFR <30 mL/min, consider dose reduction by 25% and monitor for fluid retention. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 75% or use alternative. |
| Pediatric use | 0.1-2 mg/kg/day orally once daily or divided every 12-24 hours; maximum 60 mg/day. |
| Geriatric use | Start at lowest effective dose (e.g., 5 mg/day), increase slowly; monitor for osteoporosis, hyperglycemia, and fluid retention. |
| 1st trimester | Associated with increased risk of oral clefts and other malformations; use only if clearly needed. |
| 2nd trimester | May cause fetal growth restriction and adrenal suppression; use only if benefit outweighs risk. |
| 3rd trimester | Potential neonatal adrenal suppression and hypoglycemia; avoid prolonged use near term. |
Clinical note
Comprehensive clinical and safety monograph for ORASONE (ORASONE).
| Placental transfer | Prednisolone crosses the placenta; approximately 10-20% of maternal concentration reaches fetus. The placenta converts prednisone to prednisolone; fetal exposure is higher with prednisolone. |
| Breastfeeding | Prednisolone is excreted into breast milk in small amounts. Risk to infant is low but monitor for possible adrenal suppression, growth delay, or immunosuppression. Consider lowest effective dose and avoid high-dose or prolonged therapy. |
■ FDA Black Box Warning
None explicitly listed; however, long-term use carries risks of adrenal suppression, osteoporosis, and increased susceptibility to infections. Avoid abrupt cessation after prolonged therapy.
| Serious Effects |
Systemic fungal infectionHypersensitivity to prednisolone or any component
| Precautions | Adrenal suppression with prolonged use or high doses, Increased risk of infections, Osteoporosis with long-term use, Gastrointestinal perforation or bleeding, Cushing's syndrome, Growth suppression in children, Myopathy, Ocular effects (cataracts, glaucoma), Psychiatric disturbances, Thrombotic events |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase prednisone levels. Limit high-sodium foods to reduce fluid retention. Increase intake of potassium-rich foods (bananas, oranges) to counteract potassium depletion. Calcium and vitamin D supplementation recommended to prevent bone loss. |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | FDA Pregnancy Category D. First trimester: increased risk of cleft palate (odds ratio 3-4), oral cleft; second/third trimester: fetal adrenal suppression, intrauterine growth restriction, premature birth; chronic use associated with premature rupture of membranes. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, signs of infection; fetal ultrasound for growth restriction, preterm labor; assess for premature rupture of membranes; fetal heart rate monitoring if preterm labor. |
| Fertility Effects | May impair fertility (oligospermia, anovulation) via hypothalamic-pituitary-adrenal axis suppression; reversible upon discontinuation; animal studies show reduced fertility. |
| Clinical Pearls | Prednisone is a prodrug requiring hepatic conversion to prednisolone. In hepatic impairment, consider using prednisolone directly. Taper dose to avoid adrenal crisis. Monitor for hyperglycemia, especially in diabetics. Co-administer with food to reduce GI irritation. Avoid live vaccines during therapy. |
| Patient Advice | Take exactly as prescribed; do not stop abruptly. · Take with food or milk to prevent stomach upset. · Avoid close contact with people who have infections. · Report any signs of infection, unusual bruising, or mood changes. · Carry a medical alert card indicating you take steroids. · Do not receive live vaccines while on this medication. · Limit sodium intake and increase potassium-rich foods. · Monitor blood sugar if diabetic; steroid may increase levels. |